Basilea reported positive topline results for the first cohort of the Phase II FIDES-01 trial testing FGFR inhibitor derazantinib in patients with intrahepatic cholangiocarcinoma ("iCCA") and confirmed FGFR fusions. The objective response rate ("ORR") of 20.4% is in line with previously reported efficacy data from an earlier interim analysis (21%) and previous Phase I / II trial, while median progression free survival ("mPFS") of 6.6 months is comparable to other late stage and approved FGFR inh ....
12 Feb 2021
Derazantinib Phase II topline data confirms efficacy and moderate safety profile
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Derazantinib Phase II topline data confirms efficacy and moderate safety profile
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
12 Feb 2021 -
Author:
KIERON BANERJEE -
Pages:
5
Basilea reported positive topline results for the first cohort of the Phase II FIDES-01 trial testing FGFR inhibitor derazantinib in patients with intrahepatic cholangiocarcinoma ("iCCA") and confirmed FGFR fusions. The objective response rate ("ORR") of 20.4% is in line with previously reported efficacy data from an earlier interim analysis (21%) and previous Phase I / II trial, while median progression free survival ("mPFS") of 6.6 months is comparable to other late stage and approved FGFR inh ....